Filtered By:
Specialty: Cardiology
Drug: Clopidogrel
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 545 results found since Jan 2013.
Potential role for pentoxifylline as an anti-inflammatory drug for patients with acute coronary syndrome
Exp Ther Med. 2022 Jun;23(6):378. doi: 10.3892/etm.2022.11305. Epub 2022 Apr 8.ABSTRACTThe link between inflammation and acute coronary syndrome (ACS) remains to be sufficiently elucidated. It has been previously suggested that there is an inflammatory process associated with ACS. Pentoxifylline, a methylxanthine derivate, is known to delay the progression of atherosclerosis and reduce the risk of vascular events, especially by modulating the systemic inflammatory response. The present study is a single-blind, randomized, prospective study of pentoxifylline 400 mg three times a day (TID) added to standard therapy vs. stand...
Source: Atherosclerosis - May 2, 2022 Category: Cardiology Authors: Daniel Miron Brie Cristian Mornos Diduta Alina Brie Constantin Tudor Luca Lucian Petrescu Madalina Boruga Source Type: research
Comparison of Ticagrelor With Clopidogrel in East Asian Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
In this study, PubMed, EMBASE, Cochrane Library database, and other sources were systematically searched. The primary efficacy outcome was all-cause death, the primary safety outcomes were any bleeding, PLATO major bleeding, and fatal bleeding. The secondary outcomes included vascular-cause death, myocardial infarction, stent thrombosis, stroke, and dyspnea. A total of 8 randomized controlled trials with 3597 patients met inclusion criteria. Compared with clopidogrel, ticagrelor had significantly higher incidence of any bleeding [risk ratio (RR), 1.63; 1.33–1.99; P
Source: Journal of Cardiovascular Pharmacology - May 1, 2022 Category: Cardiology Tags: Review Article Source Type: research
Antiplatelet regimens after ischemic stroke or transient ischemic attack: a systematic review and updated network meta-analysis
CONCLUSIONS: The efficacy and safety profiles among antiplatelet regimens may differ according to clinical situation, although cilostazol, aspirin plus clopidogrel, and aspirin plus dipyridamole may be considered as preferable options.PMID:35402589 | PMC:PMC8987873 | DOI:10.21037/atm-21-3748
Source: Atherosclerosis - April 11, 2022 Category: Cardiology Authors: Seung Jin Jung Bum Joon Kim Chi Kyung Kim Sung Ryul Shim Jin-Man Jung Source Type: research
Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines
Stroke Vasc Neurol. 2022 Apr 7:svn-2021-001166. doi: 10.1136/svn-2021-001166. Online ahead of print.ABSTRACTAntiplatelet therapy is one of the mainstays for secondary stroke prevention. This narrative review aimed to highlight the current evidence and recommendations of antiplatelet therapy for stroke prevention.We conducted advanced literature search for antiplatelet therapy. Landmark studies and randomised controlled trials evaluating antiplatelet therapy for secondary stroke prevention are reviewed. Results from Cochrane systematic review, pooled data analysis and meta-analysis are discussed.Single-antiplatelet therapy ...
Source: Atherosclerosis - April 8, 2022 Category: Cardiology Authors: Jay Shah Shimeng Liu Wengui Yu Source Type: research
Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory: Report of the AAN Guideline Subcommittee
Neurology. 2022 Mar 22;98(12):486-498. doi: 10.1212/WNL.0000000000200030.ABSTRACTBACKGROUND AND OBJECTIVES: To review treatments for reducing the risk of recurrent stroke or death in patients with symptomatic intracranial atherosclerotic arterial stenosis (sICAS).METHODS: The development of this practice advisory followed the process outlined in the American Academy of Neurology Clinical Practice Guideline Process Manual, 2011 Edition, as amended. The systematic review included studies through November 2020. Recommendations were based on evidence, related evidence, principles of care, and inferences.MAJOR RECOMMENDATIONS: ...
Source: Atherosclerosis - March 22, 2022 Category: Cardiology Authors: Tanya N Turan Osama O Zaidat Gary S Gronseth Marc I Chimowitz Antonio Culebras Anthony J Furlan Larry B Goldstein Nestor R Gonzalez Julius G Latorre Steven R Mess é Thanh N Nguyen Rajbeer S Sangha Michael J Schneck Aneesh B Singhal Lawrence R Wechsler Al Source Type: research
P2Y12 Reaction Units and Clinical Outcomes in Acute Large Artery Atherosclerotic Stroke: A Multicenter Prospective Study
CONCLUSIONS: Acute PRU evaluation possesses predictive value for recurrent ischemic stroke, especially within 7 days in AIS/TIA with LAA.PMID:35249906 | DOI:10.5551/jat.63369
Source: Journal of Atherosclerosis and Thrombosis - March 7, 2022 Category: Cardiology Authors: Kazuki Fukuma Hiroshi Yamagami Masafumi Ihara Tomotaka Tanaka Toshiyuki Miyata Shigeki Miyata Koichi Kokame Kunihiro Nishimura Yuriko Nakaoku Haruko Yamamoto Mikito Hayakawa Kenji Kamiyama Yukiko Enomoto Ryo Itabashi Eisuke Furui Yasuhiro Manabe Masayuki Source Type: research
Current status of antithrombotic therapy and in-hospital outcomes in patients with atrial fibrillation undergoing percutaneous coronary intervention in Germany
CONCLUSION: The preferred therapy after PCI in patients with AF is DAT with a NOAC and clopidogrel. In-hospital ischemic and bleeding events were rare. The recommended durations for combination therapy vary considerably.PMID:35243515 | DOI:10.1007/s00059-022-05099-6
Source: Herz - March 4, 2022 Category: Cardiology Authors: Uwe Zeymer Ralph Toelg Harm Wienbergen Hans-Peter Hobbach Alessandro Cuneo Raffi Bekeredjian Oliver Ritter Birgit Hailer Klaus Hertting Marcus Hennersdorf Werner Scholtz Peter Lanzer Harald Mudra Markus Schwefer Peter-Lothar Schwimmbeck Christoph Liebetra Source Type: research
